Although three large randomized prospective clinical trials have demonstrated that postoperative radiotherapy in patients with adverse pathological features reduces prostate-specific antigen recurrence and may decrease clinical failure, this approach has not gained widespread acceptance, likely because the data strongly support such an approach only in men with Gleason ≥7 with positive surgical margins.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.